CHEK2 Gene Mutations Predispose to Papillary Thyroid Cancer
the Cancer Therapy Advisor take:
According to a study published in the International Journal of Cancer, researchers in Poland have found that cell cycle checkpoint kinase 2 (CHEK2) mutations predispose a person to thyroid cancer, familial aggregations of breast and thyroid cancer, and to double primary cancers of the breast and thyroid.
Mutations in the CHEK2 tumor suppressor gene are known to be associated with an increased risk for developing breast and prostate cancers, and because there may be a genetic association between breast and thyroid cancer, researchers sought to characterize the association of CHEK2 mutations with thyroid cancer.
For the study, researchers genotyped 468 unselected patients with papillary throid cancer and 468 matched cancer-free controls for four specific CHEK2 mutations.
Researchers also compared the family histories of patients with a CHEK2 mutation to their matched non-carriers. Results showed that 15.6% of unselected patients with papillary thyroid cancer had a CHEK2 mutations compared to 6.0% of matched controls (OR = 3.3; P < 0.0001).
In addition, researchers found that carriers of a CHEK2 mutations reported a family history of breast cancer over two times more often than non-carriers (16.4% versus 8.1%; P = 0.05). Researchers also found that seven of 11 women diagnosed with multiple primary cancers of the thyroid and breast (OR = 10; P = 0.0004).
Checkpoint kinase 2 (CHEK2) mutations predispose a person to thyroid cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Aspirin and Colorectal Cancer
- Study Reveals Scope of Genomic Variation Within Cancer Cell Lines
- IL-23 Drives Castration-Resistant Prostate Cancer
- Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer
- Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer
- FDA Grants Accelerated Approval to Nivolumab for Small Cell Lung Cancer
- Accelerated Intensity-Modulated Radiotherapy May Improve Outcomes in Localized Lung Cancer
- FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma
- COPD May Not Affect Survival in Patients With Small Cell Lung Cancer
- Prescription Drug Coverage in Medicare Part D Is Tied to a Survival Advantage in Myeloma